{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-009884","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.975279+00:00","generated_at":"2026-05-18T01:05:05.524559+00:00","sec_items":["2.02","8.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix reports preliminary Q2 net operating loss of $26.3M, cash $125.3M, runway to Q3 2026","bullets":["Net operating loss of $26.3M in Q2 2025, improved from $78.8M in Q2 2024.","Cash and equivalents $125.3M at June 30; additional $50.6M raised in Q3 2025 equity offerings.","Net cash used in ops $16.3M ($9.9M in Q2 2024); capex $1.1M (nil prior year).","Revenue from marketed products $2.0M, down from $2.2M YoY.","Company expects runway into Q3 2026; shares outstanding 8.7M as of July 25."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-009884","json":"https://secwatch.observer/filing/0001999371-25-009884.json","markdown":"https://secwatch.observer/filing/0001999371-25-009884.md","text":"https://secwatch.observer/filing/0001999371-25-009884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/0001999371-25-009884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/tnxp-8k_072525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:05:05.524559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}